Cookie Preference

This website uses cookies to improve user experience. Please select an option.  Privacy Policy

No cookies except for those necessary for technical reasons are set.

Search

Search results

[Translate to English:]

Formula Pharmaceuticals, a partner of the Max Delbrück Center for Molecular Medicine (MDC) has merged with cell therapy specialist CoImmune, with CoImmune as the surviving company. The new entity will continue its strategic partnership with the MDC.

Ascenion has supported the 20 parties of the European LifeTime research consortium in agreeing the legal framework for their scientific cooperation.

The Helmholtz-Institute for Pharmaceutical Research Saarland (HIPS), a location of the Helmholtz Centre for Infection Research (HZI), teams up with…

Ascenion GmbH, the technology transfer partner of the Helmholtz Centre for Infection Research (HZI), has supported the negotiations for a…

19 September 2016, Munich – Ascenion GmbH, the technology transfer partner of the Max Delbrück Center for Molecular Medicine in the Helmholtz…

Cancer-fighting gene therapy

As recently announced by Ascenion’s portfolio company Protectimmun, the three parties have agreed that Janssen will financially support preclinical…

The negotiation of a licensing and cooperation agreement between Formula Pharmaceuticals and the Helmholtz Association’s Max Delbrück Center for…